SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

Tuesday, September 25, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

JERSEY CITY, N.J., Sept. 25, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative

therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the following upcoming investor conferences:

  • The Ladenburg Thalmann 2018 Healthcare Conference at the Sofitel
    New York on Tuesday, October 2, 2018 at 10:30 a.m. ET.
  • Cantor Fitzgerald's Global Healthcare Conference at InterContinental New York Barclay on Wednesday, October 3, 2018 at 2:15 p.m. ET.

Live webcasts of the presentations will be available on the Investors section of the Company's website: www.scynexis.com. A replay of each presentation will be available approximately two hours after the event and will be available for two weeks following each presentation.

About SCYNEXISSCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. SCYNEXIS's lead product candidate, ibrexafungerp (formerly SCY-078), is a novel oral/IV antifungal agent in Phase 2 clinical and pre-clinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.

CONTACT:

Investor RelationsNatalie WildenradtArgot PartnersTel: 212-600-1902natalie@argotpartners.com

Media RelationsGeorge E. MacDougallMacDougall Biomedical CommunicationsTel: 781-235-3093george@macbiocom.com

Cision View original content:http://www.prnewswire.com/news-releases/scynexis-inc-to-present-at-upcoming-investor-conferences-300717295.html

SOURCE SCYNEXIS, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store